Participated · Series B · Jan 2026

Cambium fuses artificial intelligence, chemical informatics, and high-performance computing to create entirely new monomers and polymers hundreds of times faster than traditional R&D methods. The company then manufactures, tests, and scales these materials in-house on proprietary, aerospace-qualified production lines located in the U.S., the U.K., and Europe, enabling rapid prototyping and immediate scale-up for supply-chain security. Its product portfolio already includes ultra-high-temperature polymers, carbon-carbon thermal protection systems (ApexShield 1000™), machining-ready composite billets for solid-rocket motors, and metal-to-composite adhesives for air and space structures. A common platform approach allows Cambium to extend into future verticals such as optical and directed-energy protection and high-temperature foams. The recent acquisition of SHD gives Cambium one of the world’s largest qualified prepreg, film, and adhesive capacities, strengthening its global manufacturing footprint. Active contracts on multiple defense Programs of Record and dual-use applications position Cambium as a preferred advanced-materials partner across land, sea, air, and space. Investors describe the business as driving “fast, profitable growth,” though specific revenue or user metrics were not disclosed. The new capital will fund expansion of its distributed, secure manufacturing network and accelerate its product pipeline.

Participated · Series A · Oct 2018

Glympse Bio develops bioengineered, tunable sensors designed to measure disease progression in vivo for protease‑mediated diseases. Its core platform is a biosensor technology intended for applications in fibrotic diseases such as NASH, as well as oncology and infectious diseases. The company was founded in 2015 as an MIT spin‑out and is led by President & CEO Caroline J. Loew, Ph.D., and CSO Wendy Winckler, Ph.D. In October 2019 Glympse announced a strategic collaboration with Gilead Sciences to evaluate the technology as both a diagnostic and prognostic tool. In July 2020 the company closed a $46.7M Series B to continue development of its platform. Board and observer seats were added in connection with the financing, reflecting investor involvement. Glympse Bio is developing an in vivo sensing platform that uses bioengineered activity sensors to noninvasively detect human diseases and monitor drug response. The sensors are designed to travel to sites of disease, directly interrogate biological activity, and emit signals that can be detected noninvasively from a patient’s urine; they can be administered in a minimally invasive manner with selectable analytical readouts. The company reports validation of the technology in 10 different diseases using multiple delivery methods and a broad range of analytical readouts. Its lead indication targets non-alcoholic steatohepatitis (NASH), which the article states affects more than 100 million people worldwide and over 15 million in the U.S. Proceeds from the financing will be devoted to conducting clinical trials and advancing the pipeline in NASH and cancer into the clinic, and Glympse has signed multiple collaborations in NASH with pharmaceutical companies. Glympse is a spinout from the laboratory of Sangeeta Bhatia at MIT and is based at the Lab Central incubator in Cambridge, MA.

Participated · Equity · Aug 2017

Upside Foods, led by CEO Dr. Uma Valeti, is developing a way to grow real meat, poultry and seafood directly from animal cells without raising or slaughtering animals. The company raised $400M in a Series C to support commercialization and scale-up. Upside plans to use the funds to build a commercial production facility with a planned annual capacity of tens of millions of pounds of cultivated meat products and an initial focus on chicken. The facility is being designed to produce any species in both ground and whole-cut formats. Proceeds will also be used to build a supply chain for critical cell feed components to reduce costs and enable greater scale, and to invest in R&D for next-generation cultivated products. Other priorities include enhancing consumer education and continuing to grow its more than 170-person team; pending regulatory review, Upside expects to be available to U.S. consumers later this year. Memphis Meats develops methods to produce meat, poultry and seafood directly from animal cells without breeding or slaughtering animals. Led by co-founder and CEO Uma Valeti, M.D., the company demonstrated a cell-based meatball in February 2016 and a cell-based poultry product in March 2017. It plans to build a pilot production facility, continue growing its team, and launch products into the market. The company completed a $161m Series B and has raised more than $180m in total funding to date. The round also extends Memphis Meats’ coalition into Asia, which the company sees as a strategically valuable market. Memphis Meats develops cell-cultured “clean meat,” having already synthesized beef, chicken and duck in small-scale production. The company is focused on scaling production and lowering cost so meat can be grown at commercial scale. It envisions production facilities that resemble craft breweries where meat is grown, harvested and cooked rather than slaughterhouses. Current operations are small-scale and used for testing and development; the team tests many cell varieties and can produce enough meat to feed a family of four-to-eight for a big meal. Future product work includes targeting flavor profiles and consistencies to make the tastiest meat possible. The company presents the offering as actual meat produced directly from cells rather than plant-based substitutes. Memphis Meats positions the technology as a potential large-scale alternative to conventional animal agriculture. Memphis Meats develops biologically identical meat grown from animal cells in a lab, aiming to produce real meat without industrial animal slaughter. The company cultivates cells in dishes to create ground and, eventually, formed meats such as chicken breast, steak and potentially whole turkey. It positions its products as cruelty-free and more planet-friendly than conventional animal agriculture, citing water use and foodborne-illness concerns with traditional meat. Memphis Meats operates from a Bay Area lab and has produced prototype products (including video of a beef-like product). The company aims to get its “clean meat” products on shelves within the next five years and is working to prepare consumer acceptance. Financially, it has raised a $3 million seed round and is running an Indiegogo campaign that has brought in more than $52,000 from nearly 700 backers.

Participated · Series A · Oct 2015

8i builds volumetric capture systems that stitch multiple camera feeds into three-dimensional holograms, primarily aimed at bringing celebrities and personalities into immersive AR/VR experiences. The company has focused on headset-based solutions but is moving toward phone-based augmented reality through a new app called Holo. Holo is slated to launch later this year on Google Tango–compatible devices, with the company open to supporting more basic camera configurations in the future. 8i Studios currently counts more than 100 partners using its capture technology. Growth is constrained by the technical complexity of high-end hologram creation—many captures require large, studio-grade setups—and the firm says its software is steadily improving. 8i is not pursuing hardware production and is instead anticipating more mobile volumetric capture devices that would enable simpler footage to be uploaded to its network. The company recently closed a $27 million Series B round of funding led by Time Warner Investments. 8i builds a consumer media platform that enables users to create, experience and share immersive, lifelike 3D video of real people. Its proprietary software transforms regular camera video into realistic, fully volumetric 3D video for VR, AR and the web, allowing viewers to move around people in a virtual environment while preserving human movement, face and hair detail. The company was founded in May 2014 by CEO Linc Gasking and is headquartered in Wellington, New Zealand, having since expanded to Los Angeles and San Francisco. 8i has opened a showcase studio in Culver City, Los Angeles, and plans to offer free access to the recording studios alongside community events such as workshops and demonstrations. The company announced a $13.5M venture funding round, reflecting its current financial backing. No operating metrics (revenue/users) were disclosed in the article.